Federal contract award
75A50124C00033
THE DEVELOPMENT OF ANTIMICROBIALS FOR THE TREATMENT OF RESISTANT FUNGAL AND BACTERIAL INFECTIONS - OTA
Award details
Obligations, current value and potential value describe different measures; they are never added together.
| Field | Reported value |
|---|---|
| Agency | Department of Health and Human Services |
| Office | BARDA - ASPR / DAAPPO / BARDA DCMA |
| NAICS | 541714 — Research and Development in Biotechnology (except Nanobiotechnology) |
| PSC | AN42 — HEALTH R&D SERVICES; HEALTH CARE - OTHER; APPLIED RESEARCH |
| Parent award / vehicle | Not reported |
| Set-aside | NO SET ASIDE USED. |
| Pricing type | COST SHARING |
| Obligations | $122.5M |
| Current contract value | $122.5M |
| Potential contract value / ceiling | $252.1M |
| Start date | Sep 30, 2024 |
| Current end date | Mar 31, 2032 |
| Potential end date | Dec 31, 2035 |
| Latest award activity | Jul 28, 2026 |
| Source loaded | Sep 26, 2026 |
Funding and modification history
Showing the latest 6 of 6 loaded transactions. Negative values are deobligations.
| Date | Modification | Obligation change | Description |
|---|---|---|---|
| Jul 28, 2026 | P00005 | $30.0M | THE PURPOSE OF THIS MODIFICATION IS TO EXERCISE OPTION 3 CLIN0004 AND UPDATE ATTACHMENT 1: STATEMENT OF WORK DATED JUNE 10, 2026. |
| Apr 24, 2026 | P00004 | $0 | THE PURPOSE OF THIS NO COST MODIFICATION IS TO EXTEND THE PERIOD OF PERFORMANCE FOR CLIN0001 THROUGH SEPTEMBER 30, 2031, UPDATES ARTICLE V: AGREEMENT ADMINISTRATION, AND ARTICLE VII: OBLIGATION AND PAYMENT, SECTION B. |
| Sep 15, 2025 | P00003 | $24.7M | THE DEVELOPMENT OF ANTIMICROBIALS FOR THE TREATMENT OF RESISTANT FUNGAL AND BACTERIAL INFECTIONS - OTA - EXECUTE CLIN 0003 |
| Jul 7, 2025 | P00002 | $39.1M | THE DEVELOPMENT OF ANTIMICROBIALS FOR THE TREATMENT OF RESISTANT FUNGAL AND BACTERIAL INFECTIONS - OTA |
| Oct 10, 2024 | P00001 | $0 | THE DEVELOPMENT OF ANTIMICROBIALS FOR THE TREATMENT OF RESISTANT FUNGAL AND BACTERIAL INFECTIONS - OTA |
| Sep 18, 2024 | 0 | $28.7M | THE DEVELOPMENT OF ANTIMICROBIALS FOR THE TREATMENT OF RESISTANT FUNGAL AND BACTERIAL INFECTIONS - OTA |
Estimated positioning window
Dec 31, 2034 – Jun 30, 2035
50/100
Why this recompete signal
Contract timing and recorded acquisition signals at the time of calculation.
Stored score: 50/100. Available recorded signals: 45 points.
- Contract end 2035-12-31 (3347 days from calculation)
- +5 points
- 22 historical awards in this buyer and category group
- +15 points
- 6 recorded award transactions
- +10 points
- Latest award action: 2026-07-28
- +5 points
- Parent award identifier recorded
- +0 points
- Solicitation identifier recorded
- +10 points
- Linked official forecast
- +0 points
- Calculated on
- 2026-11-01 10:17:53.997580+00:00
The historical group combines buyer, NAICS, and PSC. Multiple awards in this group do not by themselves establish repeated competitions.
Rule-based research score; it does not measure your chance of winning.
This older calculation does not retain a complete reproducible breakdown. Missing or changed inputs are not assigned invented points: Original award-value bonus input.
Recompete score calculated Nov 1, 2026.
Research next steps
- Check the linked forecast or SAM for a confirmed solicitation and current timing.
- Verify whether remaining options may extend performance beyond the current end date.
- Check the stated set-aside against the solicitation and current certifications.
- Review the award scope and buyer evidence before making a bid/no-bid decision.